The short version of IRAP fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Several of the food issues from the Mercury missions were addressed for the later Gemini missions (1965–1966). Tubes (often heavier than the foods they contained) were abandoned, gelatin coatings were added to the bite-sized cubes to help prevent them from crumbling, and simpler rehydration methods were developed. The menus were also expanded to include items such as shrimp cocktail, chicken and vegetables, toast squares, butterscotch pudding, and apple juice. The crew of Gemini 3 snuck a corned beef sandwich on their spaceflight. Mission Commander Gus Grissom loved corned beef sandwiches, so Pilot John Young brought one along, having been encouraged by fellow astronaut Walter Schirra. However, Young was supposed to eat only approved food, and Grissom was not supposed to eat anything at all. Floating crumbs from the bread posed a potential problem, causing Grissom to put the sandwich away and the astronauts were mildly rebuked by NASA for the act. A congressional hearing was called, forcing NASA deputy administrator George Mueller to promise no repeats, and NASA employed renewed vigilance regarding what astronauts brought along on future missions.
==== Data annotation and "ghost workers" ==== Beyond hardware, the development of AI models relies on massive amounts of human labour to label data, train algorithms, and moderate content. This work is frequently outsourced to business process outsourcing (BPO) firms operating in the Global South, particularly in countries like Kenya, Ethiopia, and Colombia. These data labourers, often referred to as "ghost workers", operate in what researchers describe as "digital sweatshops". Workers frequently report exploitative conditions, including low pay (sometimes as little as $2 an hour), forced unpaid overtime, and a lack of job security. Furthermore, content moderators are routinely exposed to graphic, violent, and hateful material in order to train AI safety filters. A 2025 Equidem survey of data workers documented widespread psychological harm, including PTSD, anxiety, and depression resulting from this exposure. In the UK, development experts and technology associations have argued that the UK has a responsibility to address these supply chain abuses. The Institute of Development Studies (IDS) has warned that the uncritical use of AI in international development is morally dubious, noting that AI is often built on "stolen data" labelled using the exploited labour of women in low-income countries. The IDS advocates for a "Responsible AI" approach that removes worker exploitation from the supply chain and ensures fair work practices. Furthermore, techUK, the UK's technology trade association, has criticised the UK Government for falling behind on supply chain regulation.
=== A changing profession === Since the 1970s, clinical psychology has continued growing into a robust profession and academic field of study. Although the exact number of practicing clinical psychologists is unknown, it is estimated that between 1974 and 1990, the number in the US grew from 20,000 to 63,000. Clinical psychologists continue to be experts in assessment and psychotherapy while expanding their focus to address issues of gerontology, sports, and the criminal justice system to name a few. One important field is health psychology, the fastest-growing employment setting for clinical psychologists in the past decade. Other major changes include the impact of managed care on mental health care; an increasing realization of the importance of knowledge relating to multicultural and diverse populations; and emerging privileges to prescribe psychotropic medication.
SIMS is a mass spectrometry method to measure small-scale elemental and isotopic variations of samples. Its ability to measure in spots with a narrow diameter (10–40 μm) makes it a useful tool to date small (<100 μm) mineral grains and individual domains within a single crystal. SIMS can achieve a precision of ~3%. Sensitive high-resolution ion microprobe (SHRIMP) is widely regarded as a powerful tool among SIMS. SIMS analyzes the mineral surface (a few μm) composition by sputtering the surface with a focused primary ion beam under vacuum. The secondary ions liberated from the mineral are accelerated, measured and analyzed in the mass spectrometer. Sample are analysed in rotation with a standard of known elemental or isotopic ratios in order to determine the ratios in the sample for dating.
Sources: en.wikipedia.org
Parliament passes the Electoral Amendment Act 2025, which tightens the timeframe for voter registration, bans prisoners from voting, and allows larger anonymous political donations. 17 December: Assistant Commissioner Mike Pannett is appointed as Deputy Police Commissioner. The New Zealand Government agrees to return 3,068 hectares in the upper South Island, including the Kaiteriteri Recreation Reserve and the Abel Tasman Coast Track, plus a $420 million compensation, to Te Tau Ihu Māori as part of the Nelson Tenths settlement. Former Deputy Police Commissioner Jevon McSkimming is sentenced to nine months of home detention after pleading guilty to charges of possessing objectionable material. Primary school teachers affiliated with the New Zealand Educational Institute reject the Government's pay off of a 4.6% pay rise over the next two years. Justice Michele Wilkinson-Smith of the Wellington High Court rules in favour of PATHA's bid to delay an incoming ban on new puberty blocker prescriptions expected to come into effect on 19 December, pending a judicial review. Justice Pheroze Jagose of the Auckland High Court dismisses food processing company Talley's Group's defamation case against broadcaster TVNZ and journalist Thomas Mead over a 2021 story covering its Ashburton plant. One new case of measles is reported in Queenstown, bringing the total number of cases nationwide to 32. Four cases were active at the time.
A number of independent candidates announced presidential runs, most notably Robert F. Kennedy Jr. and Cornel West. Several third parties, including the Libertarian Party, the Green Party, the Party for Socialism and Liberation, the Constitution Party, and the American Solidarity Party also announced presidential nominees. Kennedy dropped out of the race in August 2024, although he remained on the ballot in many states. The No Labels organization abandoned its efforts to run a centrist candidate in April 2024.
Helium II is a superfluid, a quantum mechanical state of matter with strange properties. For example, when it flows through capillaries as thin as 10 to 100 nm it has no measurable viscosity. However, when measurements were done between two moving discs, a viscosity comparable to that of gaseous helium was observed. Existing theory explains this using the two-fluid model for helium II. In this model, liquid helium below the lambda point is viewed as containing a proportion of helium atoms in a ground state, which are superfluid and flow with exactly zero viscosity, and a proportion of helium atoms in an excited state, which behave more like an ordinary fluid. In the fountain effect, a chamber is constructed which is connected to a reservoir of helium II by a sintered disc through which superfluid helium leaks easily but through which non-superfluid helium cannot pass. If the interior of the container is heated, the superfluid helium changes to non-superfluid helium. In order to maintain the equilibrium fraction of superfluid helium, superfluid helium leaks through and increases the pressure, causing liquid to fountain out of the container. The thermal conductivity of helium II is greater than that of any other known substance, a million times that of helium I and several hundred times that of copper. This is because heat conduction occurs by an exceptional quantum mechanism. Most materials that conduct heat well have a valence band of free electrons which serve to transfer the heat. Helium II has no such valence band but nevertheless conducts heat well.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.